Drug Delivery Stocks List
Symbol | Grade | Name | % Change | |
---|---|---|---|---|
HVPE | F | HarbourVest Global Private Equity | -1.09 | |
0NTI | B | Gerresheimer AG | 0.00 |
Related Industries: Asset Management
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
EDIV | B | Lyxor S&P Eurozone ESG Dividend Aristocrats (DR) UCITS ETF EUR Acc GBP | 1.16 | |
DJSC | B | iShares EURO STOXX Small UCITS ETF | 1.13 | |
MMS | C | Lyxor Index Fund | 0.79 | |
UB69 | A | UBS MSCI EMU Small Cap UCITS ETF | 0.74 | |
CES1 | A | iShares MSCI EMU Small Cap UCITS ETF | 0.73 |
Compare ETFs
- Drug Delivery
Drug delivery refers to approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effect. It may involve scientific site-targeting within the body, or it might involve facilitating systemic pharmacokinetics; in any case, it is typically concerned with both quantity and duration of drug presence. Drug delivery is often approached via a drug's chemical formulation, but it may also involve medical devices or drug-device combination products. Drug delivery is a concept heavily integrated with dosage form and route of administration, the latter sometimes even being considered part of the definition.Drug delivery technologies modify drug release profile, absorption, distribution and elimination for the benefit of improving product efficacy and safety, as well as patient convenience and compliance. Drug release is from: diffusion, degradation, swelling, and affinity-based mechanisms. Some of the common routes of administration include the enteral (gastrointestinal tract), parenteral (via injections), inhalation, transdermal, topical and oral routes. . Many medications such as peptide and protein, antibody, vaccine and gene based drugs, in general may not be delivered using these routes because they might be susceptible to enzymatic degradation or can not be absorbed into the systemic circulation efficiently due to molecular size and charge issues to be therapeutically effective. For this reason many protein and peptide drugs have to be delivered by injection or a nanoneedle array.
For example, many immunizations are based on the delivery of protein drugs and are often done by injection.
Current efforts in the area of drug delivery include the development of targeted delivery in which the drug is only active in the target area of the body (for example, in cancerous tissues), sustained release formulations in which the drug is released over a period of time in a controlled manner from a formulation, and methods to increase survival of peroral agents which must pass through the stomach's acidic environment. In order to achieve efficient targeted delivery, the designed system must avoid the host's defense mechanisms and circulate to its intended site of action. Types of sustained release formulations include liposomes, drug loaded biodegradable microspheres and drug polymer conjugates. Survival of agents as they pass through the stomach typically is an issue for agents which cannot be encased in a solid tablet; one research area has been around the utilization of lipid isolates from the acid-resistant archaea Sulfolobus islandicus, which confers on the order of 10% survival of liposome-encapsulated agents.
Recent Comments
- TraderMike on Trades of the Week: Jan 8 - Jan 12, 2024
- Magneto296 on Trades of the Week: Jan 8 - Jan 12, 2024
- SwingTradeBot on Market Recap for Tuesday, February 27, 2024
- SwingTradeBot on Market Recap for Monday, February 26, 2024
- SwingTradeBot on Market Recap for Friday, February 23, 2024
From the Blog
Featured Articles